Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

Gilead’s efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. The approval of Yeztugo for PrEP is a major boost for the company.